Recently, in vivo RNAi screening had identified activation of the mitogen-activated protein kinase 14 (MAPK14)-activating transcription factor 2 (ATF2)-axis as a novel mechanism driving sorafenib resistance in HCC [11]. This evidence concerns the gene MAPK14 and hepatocellular carcinoma.